Vericel (VCEL) 10-K2010 FY Annual report

Filed: 7 Sep 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: advisor, Alteon, ATEK, atherosclerotic, Bachelor, banker, bankruptcy, Bartel, billion, Biochemistry, Biology, BS, budgeted, cardiopulmonary, career, catheter, Chemistry, chest, commonly, concept, confirmed, constriction, contact, coronary, court, Delaware, delivery, diagnostic, disruption, doubling, Dr, Durbin, Electronic, ElMa, engraftment, Esperion, exacerbate, forego, forward, Graduate, graphic, Harold, Harvest, hyperlipidemia, incision, increasingly, inRule, Intelligent, invasive, jeopardizing, Kellogg, Lehman, mechanism, MicroCap, MicroIslet, mixed, ml, mouse, MPH, negotiated, Neostem, NightHawk, Northwestern, novo, NYHA, obesity, obstruction, Oppenheimer, opposed, optimization, optimized, output, PAD, pathway, Pfizer, postdoctoral, Prescient, promise, pronouncement, proportional, pursuit, Radiology, rat, RDG, RealBio, retroactive, revealed, reversal, reverse, risky, Ronnda, scale, science, Scientist, Scott, shortage, SPA, SRS, statistical, statistically, stroke, survival, Tabor, Tengion, tightening, toxin, Transom, underwriter, underwriting, unmet, Urschel, usage, venture, viability, Wagner, Walkersville, wholesale, Wolverine, Yale, York

Removed: accounted, accuracy, accurate, acting, adult, aid, amendment, Amersham, analgesic, anecdotal, announced, APB, appeal, assert, assure, ATMP, attestation, Auburn, automated, avascular, Bad, Beaumont, bid, BRC, buy, canceled, Centro, characteristic, collateralized, collection, compassionate, compensating, Competent, confidence, CTA, decision, delayed, delisted, depositing, DepoTech, diabetic, dilute, directive, discount, distributed, Domestic, Dossier, Dot, efficiency, Electrical, EMEA, England, Epic, equaled, Ethical, EU, executed, fact, fat, femoral, foot, formation, Foundation, fracture, Fraunhofer, frequency, furnish, furniture, generating, German, grace, grandfather, grandfathered, GTP, head, hospital, IIb, IMPD, imposition, indexed, influenced, infrastructure, initiating, injury, Interfacial, introduced, investor, irregular, Isolagen, Journal, justify, lender, LJL, loading, location, long, MA, master, MBA, medicinal, Medico, Metra, Metrika, MI, modest, modify, molecular, MRI, Oak, obligated, Oeynhausen, orthopedic, osteoblast, people, phased, Pittsburgh, plain, preliminary, prevail, Procurement, progression, promoting, pump, qualitative, Quantum, Quidel, ratably, reach, reaction, recover, recruitment, refine, reflected, reflecting, regional, reinvested, restate, returned, revised, Royal, rule, secondary, serve, serving, Spanish, spine, Stephen, Stuttgart, Sudovar, suffering, Targesome, team, Teknon, transition, TRC, union, unique, unrealized, updated, upfront, Valley, vanilla, William

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VCEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Aastrom Biosciences, Inc. (the “Company”) on Form 10-K for the year ended June 30, 2010, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), the following:

(1) The Report fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/s/Timothy M. Mayleben Timothy M. Mayleben
		President and Chief Executive Officer
		(Principal Executive Officer)

		/s/Scott C. Durbin Scott C. Durbin
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Date: September 7, 2010

A signed original of this written statement required by Section 906 has been provided to Aastrom Biosciences, Inc. and will be retained by Aastrom Biosciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.